Skip to main content
VCbacked
Log inGet Started

Enlaza Therapeutics

La Jolla, United States

Enlaza Therapeutics is a biotechnology research company.

$15.0M raised
Sep 2025
Venture - Series Unknown
BiopharmaBiotechnologyHealth CareTherapeutics

Top Investors

Lightspeed Venture PartnersSamsara BioCapitalFrazier Life SciencesRegeneronJ.P. Morgan Asset Management

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Enlaza Therapeutics

How much funding has Enlaza Therapeutics raised?
Enlaza Therapeutics has raised $15.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2025.
Who are Enlaza Therapeutics's investors?
Enlaza Therapeutics's investors include Lightspeed Venture Partners, Samsara BioCapital, Frazier Life Sciences, Regeneron, J.P. Morgan Asset Management.
Where is Enlaza Therapeutics headquartered?
Enlaza Therapeutics is headquartered in La Jolla, United States.
What does Enlaza Therapeutics do?
Enlaza Therapeutics is a biotechnology research company.
What stage is Enlaza Therapeutics at?
Enlaza Therapeutics is at the Venture - Series Unknown stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Enlaza Therapeutics — Funding & Investors." VCBacked, September 10, 2025, https://www.vcbacked.co/company/enlaza-therapeutics. Accessed June 4, 2026.
APA
VCBacked. (2025). Enlaza Therapeutics — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/enlaza-therapeutics
Wikipedia (cite web)
{{cite web |title=Enlaza Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/enlaza-therapeutics |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biopharma

View all
ParcelBio
San Francisco$13.2M
Modicus Prime
Austin
Latus Bio
Philadelphia
Ocugen
Malvern
Ember LifeSciences
Los Angeles$16.5M
ClearNote Health
San Diego